| http://www.w3.org/ns/prov#value | - WASHINGTON - The biotech and pharmaceutical makers' support for getting a follow-on biologics bill passed this year is an attempt to cut a deal with Congress to secure at least 12 years of data exclusivity, said Kathleen Jaeger, CEO of the Generic Pharmaceutical Association (GPhA). (BioWorld Today)
|
